SLC5A2 and diabetes mellitus: While diabetes induces inflammation, mitochondrial dysfunction, myocardial fibrosis, and increased oxidative stress, new hypoglycemic therapies represented by GLP-1 receptor agonists and SGLT2 inhibitors counteract the development of atherosclerosis and cardiovascular complications by reducing oxidative stress, increasing nitric oxide release, and lowering IR, hyperlipidemia, and cardiovascular risk [25].